Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
about
Antibody targeting of claudin-1 as a potential colorectal cancer therapy.Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumabMulti-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer.Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.Current biologics for treatment of biliary tract cancers.Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer.The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review).Risk factors for brain metastases in patients with metastatic colorectal cancer.
P2860
Q33850900-6ADDEB28-7CA4-4E73-A413-15336E286605Q35877954-21453525-8BC5-482A-A54C-93BE16417F59Q36141923-4B1EFDC8-4120-495A-A0ED-3BD0A29A086DQ36148358-1D949869-DC5C-44C1-8DF3-B92E6BB3F669Q37321131-B39A79D2-2671-4367-AE1E-096AD90ECC94Q37606696-68B7CC09-4F78-4988-84F4-E70FC30674FCQ37735989-28DF6D32-1879-498B-BF05-0BC20C329B49Q39453572-3EBD4FF4-B45B-47D6-807B-DB696B4D766EQ40363878-95481F64-5483-4EC2-958B-33AE19E1EDC2Q41361628-440285CC-413A-40B7-B40C-D2EF3458853EQ42316814-BB2AC190-A55D-4F94-9770-746DD3DEB1A5Q47134024-DCF73D95-E684-46CA-AE51-E81C5FBBF668Q51732351-E399B680-3577-43B3-BE8F-59E83C691810Q52097217-AC0C2FB5-255E-4E15-BBE0-8F9F14DA2C99
P2860
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@ast
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@en
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@nl
type
label
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@ast
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@en
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@nl
prefLabel
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@ast
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@en
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@nl
P2093
P3181
P1476
Extended RAS analysis for anti ...... h metastatic colorectal cancer
@en
P2093
Axel Grothey
J Randolph Hecht
Kelly S Oliner
Lee Schwartzberg
Roger Sidhu
Scott Kopetz
P3181
P356
10.1016/J.CTRV.2015.05.008
P407
P577
2015-09-01T00:00:00Z